NCT06951399View on ClinicalTrials.gov

Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

August 30, 2027

Study Completion Date

April 30, 2028

Conditions
NSCLC (Advanced Non-small Cell Lung Cancer)NSCLC Stage IV Without EGFR/ALK MutationNSCLC Adenocarcinoma
Interventions
DRUG

Pembrolizumab (KEYTRUDA®)

IV Pembrolizumab 200 mg combined with pemetrexed and platinum (investigator's choice of cisplatin or carboplatin) every 3 weeks

Trial Locations (1)

4941492

Davidoff Comprehensive Cancer Center, Rabin Medical Center, Petah Tikva

Sponsors

Collaborators (1)

MSD Pharmaceuticals LLC
All Listed Sponsors
collaborator

MSD Pharmaceuticals LLC

INDUSTRY

lead

Rabin Medical Center

OTHER

NCT06951399 - Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter